Madrigal Pharmaceuticals, Inc.

LSE:0JXI Stock Report

Market Cap: US$7.3b

Madrigal Pharmaceuticals Valuation

Is 0JXI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JXI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0JXI ($333.06) is trading below our estimate of fair value ($1968.82)

Significantly Below Fair Value: 0JXI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JXI?

Key metric: As 0JXI barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0JXI. This is calculated by dividing 0JXI's market cap by their current book value.
What is 0JXI's PB Ratio?
PB Ratio9.3x
BookUS$777.16m
Market CapUS$7.34b

Price to Book Ratio vs Peers

How does 0JXI's PB Ratio compare to its peers?

The above table shows the PB ratio for 0JXI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.7x
GNS Genus
2x37.7%UK£1.1b
AVCT Avacta Group
3.5x-2.1%UK£168.3m
OXB Oxford Biomedica
6.8x93.2%UK£447.8m
KRYS Krystal Biotech
6.4x41.2%US$5.7b
0JXI Madrigal Pharmaceuticals
9.3x73.1%US$7.3b

Price-To-Book vs Peers: 0JXI is expensive based on its Price-To-Book Ratio (9.3x) compared to the peer average (4.7x).

Price to Book Ratio vs Industry

How does 0JXI's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.50m
VAL ValiRx
0.6xn/aUS$2.81m
No more companies available in this PB range
0JXI 9.3xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0JXI is expensive based on its Price-To-Book Ratio (9.3x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0JXI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JXI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0JXI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JXI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$330.96
US$372.20
+12.5%
22.1%US$530.00US$155.00n/a15
Nov ’25US$314.44
US$366.07
+16.4%
23.8%US$530.00US$155.00n/a15
Oct ’25US$210.93
US$362.53
+71.9%
23.1%US$511.00US$150.00n/a15
Sep ’25US$245.23
US$362.53
+47.8%
23.1%US$511.00US$150.00n/a15
Aug ’25US$276.94
US$365.33
+31.9%
22.6%US$507.00US$150.00n/a15
Jul ’25US$278.07
US$365.07
+31.3%
22.6%US$507.00US$150.00n/a15
Jun ’25US$228.18
US$363.86
+59.5%
23.5%US$507.00US$150.00n/a14
May ’25US$205.42
US$377.07
+83.6%
23.0%US$565.00US$150.00n/a14
Apr ’25US$266.85
US$394.54
+47.9%
15.7%US$565.00US$270.00n/a13
Mar ’25US$250.81
US$318.92
+27.2%
18.0%US$407.00US$155.00n/a12
Feb ’25US$222.13
US$321.08
+44.5%
14.0%US$383.00US$204.00n/a12
Jan ’25US$231.32
US$315.92
+36.6%
17.9%US$383.00US$154.00n/a12
Dec ’24US$205.00
US$315.92
+54.1%
17.9%US$383.00US$154.00n/a12
Nov ’24US$133.26
US$318.25
+138.8%
21.3%US$409.00US$154.00US$314.4412
Oct ’24US$150.68
US$326.83
+116.9%
17.9%US$410.00US$224.00US$210.9312
Sep ’24US$182.05
US$334.64
+83.8%
15.8%US$409.00US$224.00US$245.2311
Aug ’24US$205.85
US$340.82
+65.6%
15.0%US$416.00US$224.00US$276.9411
Jul ’24US$230.00
US$340.82
+48.2%
15.0%US$416.00US$224.00US$278.0711
Jun ’24US$279.00
US$331.17
+18.7%
17.7%US$416.00US$224.00US$228.1812
May ’24US$310.47
US$315.83
+1.7%
18.3%US$414.00US$194.00US$205.4212
Apr ’24US$224.81
US$313.17
+39.3%
17.2%US$390.00US$194.00US$266.8512
Mar ’24US$273.00
US$313.17
+14.7%
17.2%US$390.00US$194.00US$250.8112
Feb ’24US$285.32
US$303.00
+6.2%
18.4%US$390.00US$194.00US$222.1312
Jan ’24US$298.95
US$289.75
-3.1%
16.6%US$375.00US$194.00US$231.3212
Dec ’23US$70.33
US$152.58
+117.0%
23.6%US$203.00US$75.00US$205.0012
Nov ’23US$73.51
US$152.42
+107.3%
23.5%US$203.00US$75.00US$133.2612

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Formycon

€857.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

hVIVO

UK£144.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€64.00

7D

3.6%

1Y

15.7%